The global market for precision medicine is projected to top more than $84.5 billion by 2024. Targeted therapies for rare, genetic diseases, cancer and chronic conditions come with the hope of a cure.
Companies such as Roche, Novartis, Spark Therapeutics (now owned by Roche), Pfizer, Editas Medicine, and BioMarin Pharmaceuticals are among the pharma players in this space. There seem to be new developments in precision medicine on almost a weekly basis.
So what do educational institutions need to do to create fertile ground for gene therapy research to produce the next generation of companies developing these therapies? And what needs to happen to facilitate data sharing, ensure access to genome sequencing and these promising therapies?
A new eBook highlights compelling conversations around a couple of events that took place during the JP Morgan Healthcare conference in January this year. One, hosted by the Penn Center for Innovation, offers a showcase of the latest biotech innovations emerging from Penn and the Perelman School of Medicine. Another, hosted by Deloitte and P4ML, drew attention to an initiative by the World Economic Forum to improve the way genomic data is shared to develop better treatments for rare diseases and ethical considerations for access to precision medicine.
Fill in the form below to download the eBook, The Pathway to Precision Medicine.
Picture: Getty Images
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
